文献速递急性肾损伤慢性肾脏病

外泌体在肾脏疾病中的应用:从病理生理到诊疗工具

Exosomes in kidney disease: From Pathophysiology to Diagnostic and Therapeutic Tools.
PubMed 文献 · Nephrol Dial Transplant · 2026-08-10

该叙述性综述检索了截至2026年4月的PubMed、Web of Science和Scopus数据库,总结外泌体的分类、生物学功能、技术流程及其在肾脏疾病中的生理和病理作用。外泌体通过生物活性货物参与炎症、氧化应激和纤维化等肾脏病理过程,尿液或血液外泌体分子是急慢性肾脏病的潜在无创生物标志物,细胞来源外泌体在临床前研究中显示出肾脏修复的治疗效果,但技术标准化和大规模临床验证仍是主要挑战。

要点

  • 外泌体参与调控肾脏炎症、氧化应激和纤维化等病理过程。
  • 尿液或血液外泌体分子是急慢性肾脏病的潜在无创生物标志物。
  • 细胞来源外泌体在临床前研究中显示出肾脏修复的治疗效果。

核心结论

  • 外泌体在肾脏疾病的诊断和治疗方面具有较高的转化潜力,但解决标准化、验证和监管挑战对临床采用至关重要。

研究设计与样本

  • 叙述性综述,通过全面检索PubMed、Web of Science和Scopus数据库(截至2026年4月)进行。

主要发现

  • 外泌体调控肾脏病理过程,包括炎症、氧化应激和纤维化。
  • 尿液或血液外泌体分子是急性或慢性肾脏病的潜在无创生物标志物。
  • 细胞来源外泌体在临床前研究中显示出对肾脏修复的治疗效果。

临床怎么用

  • 尿液或血液外泌体分子可作为急慢性肾脏病的潜在无创生物标志物。
  • 细胞来源外泌体在临床前研究中显示出肾脏修复的治疗效果,但尚未进入临床常规应用。

局限性

  • 技术标准化和大规模临床验证仍是显著挑战。
  • 外泌体临床转化面临标准化、验证和监管方面的障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney disease is a significant global public health and economic burden, with unmet clinical requirements for early diagnostic biomarkers and targeted therapies. Exosomes, nanoscale lipid bilayer vesicles that facilitate intercellular communication through bioactive cargo, have emerged as a promising translational tool for addressing these gaps. OBJECTIVE: This review summarizes the classification, biological functions, technical workflows (isolation, characterization, and storage), and physiological/pathological roles of exosomes in kidney disease. It also emphasizes clinically actionable advances in exosome-based diagnosis and therapy and identifies translational barriers. METHODS: This narrative review was conducted through a comprehensive literature search across PubMed, Web of Science, and Scopus databases up to April 2026. KEY FINDINGS: Exosomes regulate renal pathological processes, including inflammation, oxidative stress, and fibrosis. Urinary/blood exosomal molecules are potential non-invasive biomarkers for acute/chronic kidney disease. Cell-derived exosomes demonstrate preclinical therapeutic efficacy for renal repairs. However, technical standardization and large-scale clinical validation remain significant challenges. CONCLUSION: Exosomes have a high translational potential for the diagnosis and treatment of kidney diseases. Addressing standardization, validation, and regulatory challenges is crucial for clinical adoption, and this review provides a roadmap for bridging preclinical findings to clinical practice.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. He J, Feng J, Zhao J, et al. Exosomes in kidney disease: From Pathophysiology to Diagnostic and Therapeutic Tools. Nephrol Dial Transplant. 2026. PMID: 42573516. doi:10.1093/ndt/gfag182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。